

# Clinical Core List Of Resources

## Data

	Type of Study / Intervention	Age Range and Cognitive Status	Cognitive tests <sup>1</sup>	Initial Health Assessment <sup>2</sup>	Plasma	Plasma CAT	Serum	RBCs	CSF	CSF CAT	PBMCs	RNA	STOOL	Metabolic Panel Values	MRI <sup>3</sup>	PIB PET <sup>4</sup>	AcAc PET <sup>5</sup>	CT <sup>6</sup>
FDS (n = 182)	Observational, one visit, one time study	≥ 45 years of age, normal cognition to moderate Alzheimer's Disease (AD)	×	×														
ADPPR (n = 139)	Observational, multi-visit, longitudinal study with biennial follow-up	50 to 90 years of age, normal cognition to mild AD	×	×	×		×	×	×	×	×	×		×	×	×		
ADCC (n = 9)	Observational, multi-visit, longitudinal study with frequency of follow-up dependant on group assignment	≥ 55 years of age, normal cognition to mild AD	×	×	×		×	×	×	×	×	×		×	×	Coming soon	Coming soon	
BEAM (n = 45)	Ketogenic vs low fat diet, on each for 6 weeks	50 to 85 years of age, normal cognition to mild AD	×	×	×		×	×	×	×			×	×	×		×	
MEAL* (n = 60)	High saturated fat/glycemic index vs low saturated fat/glycemic diet for 4 weeks	≥ 50 years of age, normal cognition to mild MCI and AD	×				×	×	×									
MEAL-2 (n = 84)	High vs low fat/sugar diet for 4 weeks. Multi-site trial	45 to 65 years of age, normal cognition to mild cognitive impairment (MCI)	×	×	×		×	×	×	×				×	×			×
NI 1* (n = 66)	Insulin (high or lower dose) vs placebo	55 to 85 years of age, normal cognition to mild AD	×	×														
NI 2* (n = 92)	Insulin (5 acute doses) vs placebo	55 to 85 years of age, MCI to mild AD	×	×														
PACE-2 (n = 91)	High vs low intensity exercise for 6 months. Multi-site trial	50 to 89 years of age, normal cognition with subjective complaint to MCI	×	×	×		×	×	×	×	×	×		×	×			
PASTA* (n = 130)	4 meals with varying levels of saturated fat and glycemic index, Acute dietary challenge	50 to 90 years of age, normal cognition to MCI	×	×	×		×											
RECALL* (n = 12)	Rosiglitazone vs placebo for 24 weeks	55 to 85 years of age, mild AD	×	×	×		×											
SNIFF LONG 21* (n = 60)	Insulin detemir (high or lower dose) vs placebo for 21 days	55 to 85 years of age, mild AD	×	×														
SNIFF-Long 120 (n = 43)	Insulin detemir vs placebo for 120 days	50 to 89 years of age, MCI to mild AD	×	×	×	×	×	×	×	×				×	×			
SNIFF-PD* (n = 20)	Insulin vs placebo, 2 acute doses	≥ 45 years of age, Parkinson's Disease with memory impairment	×	×	×		×											
SNIFF-Quick (n = 26)	Insulin (aspartate) vs placebo for 12 weeks	50 to 89 years of age, MCI to mild AD	×	×	×	×	×	×	×	×	×	×		×	×			
TRIM/CLAMP* (n = 58)	Triglyceride/placebo/insulin infusions to acutely raise free fatty acids	≥ 50 years of age, normal cognition to mild AD	×	×	×		×		×									

### Superscripts

\* Archiving is in process

~ In a subset of participants

<sup>1</sup> Cognitive tests for each study may include tests of global function as well as other tests of verbal memory, visual memory, language fluency and executive function (for example, MoCA, MMSE, Shipley-2, AMNART, Logical Memory, Craft Story, Rey AVLT, BVM, Trails, Digit Span, Digit Symbol, Verbal Fluency, Category Fluency, BNT, MINT, Number Span, Benson Complex figure and FCSRT). In addition to assessing the cognitive status of our participants, many studies also assess functional status of participants using various collateral interviews, including the FAQ, the NPIQ, and the CDR.

<sup>2</sup> Initial health assessment of all participants includes at least collection of demographic data, height, weight, blood pressure, pulse, review of medical history and medications, as well as fasting glucose, insulin and A1C. For some participants, it further includes hip and waist circumference measurement, comprehensive physical and neurological exam, and additional blood work to include CMP, CBC, TSH, B12, lipid panel and PT/PTT (on a subset of participants)

<sup>3</sup> MRI imaging of the brain in most participants. Imaging sequences include T1 volume, T2 FLAIR, DTI, BOLD/fMRI, PCASL, NODDI and QSM/SWI

<sup>4</sup> PET scan with PIB compound for amyloid imaging of the brain in subset of participants

<sup>5</sup> PET scan using two tracers (11C-acetoacetate and 18F-fluorodeoxyglucose), to image metabolism in the brain of subset of BEAM study participants

<sup>6</sup> Abdominal CT scan collected before and after diet intervention